Key Takeaways:
- Aging Pet Tailwind: Pets aged 5 and older are driving growth in both wellness and non-wellness visits, a trend that has held for multiple straight quarters.
- Price Projection: Based on current execution, IDXX stock could reach $710 by December 2028.
- Potential Gains: This target implies a total return of 33% from the current price of $535.38.
- Annual Return: Investors could see roughly 13% annual growth over the next 2.3 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
IDEXX Laboratories (IDXX) delivered a strong Q2, with revenue up 10% and organic growth of 9%. The standout number was CAG Diagnostics recurring revenue, which grew over 10% organically, with double-digit gains in both the U.S. and international markets.
Operating margins expanded by 110 basis points, and earnings per share came in at $4.27, up 15% on a comparable basis.
The results were strong enough that management raised its full-year guidance across revenue, organic growth, and EPS.
There’s a catch, though. U.S. same-store clinical visits declined 1.3% in the quarter, continuing a trend that’s weighed on the stock.
Wellness visits in particular remain soft, down nearly 3%, as pet owners hold back on discretionary vet trips amid inflation and higher costs elsewhere.
Despite the underlying growth engine working well, IDXX trades well below where it stood a year ago.
See analysts’ full growth forecasts and estimates for IDXX stock (It’s free) >>>
What the Model Says for IDEXX Labs Stock
We looked at IDEXX through its position as the clear leader in veterinary diagnostics, a company that keeps growing even when the number of vet visits isn’t.
The gap between IDEXX’s revenue growth and actual clinic visits is the key story here.
In the U.S., IDEXX grew CAG Diagnostics’ recurring revenue about 1,100 basis points faster than clinical visit growth.
That premium comes from customers running more tests per visit, not from more people walking through the door.
Only about 1 in 10 U.S. wellness visits include bloodwork today, and internationally that number is even lower, leaving a long runway for diagnostic adoption to keep climbing regardless of visit trends.
The company’s innovation pipeline is also firing on multiple fronts.
Its inVue Dx cytology analyzer has placed over 9,000 units since launch, one of the most successful rollouts in company history, and IDEXX just added a new detection application (FNA) that lets vets evaluate lumps and bumps in real time.
Cancer Dx, the company’s blood-based cancer screening test, has crossed 10,000 clinics globally, with 20% of orders coming from practices that switched over from competitor labs.
Notably, Cancer Dx will expand into mast cell tumor detection later this year at no extra cost to customers, which management expects will widen adoption even further.
Using a forecast of 9.2% annual revenue growth and 33.4% operating margins, our model projects the stock could reach $710 within 2.3 years. This assumes a 34.2x price-to-earnings multiple, in line with IDEXX’s current multiple of 34.2x, but well below its longer-term averages of 42-50x.
That compression reflects lingering caution around the broader pet visit slowdown, even as the company’s own numbers keep outperforming that backdrop.
Our Valuation Assumptions
Estimate a company’s fair value instantly (Free with TIKR) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for IDXX stock:
1. Revenue Growth: 9.2%
This sits just below IDEXX’s 10.4% growth over the past year and roughly in line with its 5-year and 10-year averages.
It reflects continued strength in diagnostics recurring revenue, offset slightly by ongoing softness in U.S. clinical visits.
2. Operating margins: 33.4%
Margins have been on a steady upward path, helped by gross margin expansion from recurring revenue growth and favorable product costs.
Management continues to invest in commercial expansion and R&D, but strong volume growth continues to outpace those added costs.
3. Exit P/E Multiple: 34.2x
IDXX currently trades at this same multiple, but its historical averages run notably higher, between 42x and 50x over the past 1 to 15 years.
Our model holds the multiple flat rather than assuming expansion, reflecting some caution until vet visit trends stabilize.
Together, these assumptions point to a target price of $710.40 by the end of 2028, a 32.7% total return, or about 12.9% annualized.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
IDEXX’s growth depends on how much diagnostic testing keeps expanding per visit, even if visit counts stay soft. Here’s how the stock might perform through 2030 under different scenarios:
- Low Case: If revenue growth slows to 8.3% and net income margins settle at 25.8%, investors could still see a 37.1% total return, or 7.6% annually.
- Mid Case: With 9.2% growth and 27.4% margins, the stock could deliver a 72.1% total return, or 13.4% annually.
- High Case: If new products like Cancer Dx and inVue Dx FNA scale faster than expected, pushing revenue growth to 10.2% and margins to 28.7%, total return could reach 110.4%, or 18.8% annually.
See what analysts think about IDXX stock right now (Free with TIKR) >>>
The range reflects the impact of low lab visits, new products, and other relevant factors.
In the low case, new products are not received well, and pet lab visits remain low due to inflation and other factors, leading to very poor revenue and margin growth.
In the high case, new products like Cancer Dx and inVue Dx FNA scale faster than expected, driving higher revenue and improving margins.
How Much Upside Does IDEXX Labs Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
